Lead Product(s) : CAN10
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The new results show potent activity of a CAN10 surrogate antibody, which reduced inflammation and fibrosis in three different preclinical in vivo models of systemic sclerosis.
Product Name : CAN10
Product Type : Antibody
Upfront Cash : Inapplicable
August 11, 2022
Lead Product(s) : CAN10
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Biogen
Deal Size : $88.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Biogen will gain exclusive global regulatory, manufacturing, and commercial rights to Xcimzaneâ„¢ and will be the Marketing Authorization Holder.
Product Name : Xcimzane
Product Type : Antibody-drug Conjugate
Upfront Cash : $8.0 million
July 02, 2022
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Biogen
Deal Size : $88.0 million
Deal Type : Licensing Agreement
Lead Product(s) : PulmoStem
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $6.9 million
Deal Type : Public Offering
Details : The funds will now be deployed to advance the company's preclinical portfolio of cell therapy candidates based on mesenchymal stem cells (MSC) from amniotic fluid. Lead candidate PulmoStemâ„¢, a first-in-class treatment for pulmonary disease is scheduled...
Product Name : PulmoStem
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 07, 2021
Lead Product(s) : PulmoStem
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $6.9 million
Deal Type : Public Offering
Lead Product(s) : Imlifidase,Efgartigimod
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Argenx
Deal Size : Undisclosed
Deal Type : Collaboration
Hansa Biopharma Enters Preclinical Research Collaboration with Argenx
Details : The preclinical research collaboration is set up to explore the potential of combining imlifidase, Hansa’s IgG antibody-cleaving enzyme, and efgartigimod, argenx’s FcRn antagonist, which are both in development for indications known to be driven by d...
Product Name : Idefirix
Product Type : Enzyme
Upfront Cash : Undisclosed
March 29, 2021
Lead Product(s) : Imlifidase,Efgartigimod
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Argenx
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : CAN10
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Cantargia AB
Deal Size : Undisclosed
Deal Type : Agreement
BioInvent and Cantargia Sign Manufacturing Agreement for Monoclonal Antibody CAN10
Details : CAN10 is fully humanized monoclonal antibody targeting IL1RAP. BioInvent will provide process development, scale-up, supply of material for toxicological studies and clinical grade material in 1000L scale for use in phase I and II clinical trials.
Product Name : CAN10
Product Type : Antibody
Upfront Cash : Undisclosed
November 26, 2020
Lead Product(s) : CAN10
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Cantargia AB
Deal Size : Undisclosed
Deal Type : Agreement